PVLA | Ticker Profile - Titan Protect

PVLA

Palvella Therapeutics, Inc.

Healthcare · Biotechnology · NGM

$108.67

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.7B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-17.40

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-34.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$225.00

+107% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 16 analysts covering this stock

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.

https://palvellatx.com

Country: United States Employees: 29 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

1.687

Excellent risk-adjusted returns

Kelly Fraction

0.1496

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

6.722

Returns exceed worst-case losses — strong risk profile

Annual Return

250.0%

Historical annualised return based on price data

Max Drawdown

-37.2%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$151.18

28% below the year high

52W Low

$20.20

438% above the year low

Avg Volume

246,380

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

17.0%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-4.17

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

8.77

Heavy leverage — higher financial risk if revenues decline

Current Ratio

28.88

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

28.73

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-21,601,500

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-49,297,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$270.00

Target Median

$225.00

Target Low

$205.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go